Hidradenitis Suppurativa (HS) — Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report — 2023 To 2033
Hidradenitis suppurativa (HS), also known as acne inversus, is a chronic inflammatory skin disorder characterized by lesions such as deep-seated nodules, abscesses, draining tracts, and fibrotic scars. These lesions typically develop in areas where skin rubs together or where there are many sweat glands, with common sites including the axillary, groin, perianal, perineal, and inframammary regions. Depending on the stage of the disease, individuals may experience painful, tender papules, cysts, or nodules, along with areas of scar tissue. The condition may also involve the discharge of foul-smelling pus from the skin and the formation of sinus tracts under the skin. While there is no cure for HS, various treatment options are available based on the severity of the condition. For mild to moderate cases, treatment may involve the use of antibiotic creams, lotions, or washes, oral antibiotics, local steroid injections, minor surgical procedures, laser therapy, and hormone-regulating medications. In cases of more severe disease, these treatments may still be beneficial, along with injectable biologic agents, more extensive surgical procedures, oral immunosuppressive drugs, and other systemic medications.
· The prevalence of hidradenitis suppurativa is estimated to range from 0.5% to 4%, affecting approximately 11 in 100,000 individuals in the United States. Females are more commonly affected than males.
Thelansis’s “Hidradenitis Suppurativa (HS) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report — 2023 To 2033” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Hidradenitis Suppurativa (HS) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights of Hidradenitis Suppurativa (HS) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Hidradenitis Suppurativa (HS) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
Tags: Hidradenitis Suppurativa (HS), Hidradenitis Suppurativa (HS) market outlook, Hidradenitis Suppurativa (HS) competitive landscape, Hidradenitis Suppurativa (HS) market forecast, Thelansis, Primary market research, KOL insights, Competitive Intelligence (CI)
